Editorial
doi: 10.1158/1078-0432.CCR-10-1857.
Epub 2010 Aug 24.
Food and oral antineoplastics: more than meets the eye
- PMID: 20736331
- DOI: 10.1158/1078-0432.CCR-10-1857
Item in Clipboard
Editorial
Food and oral antineoplastics: more than meets the eye
Clin Cancer Res.
.
Abstract
Food can alter the bioavailability of orally administered drugs. Description of food effects in product labels and information about administration in relation to food are influenced by a variety of factors. Because food effects can change drug efficacy and toxicity, it is important that physicians and patients be aware of them.
Comment on
-
Inconsistent labeling of food effect for oral agents across therapeutic areas: differences between oncology and non-oncology products.Clin Cancer Res. 2010 Sep 1;16(17):4446-51. doi: 10.1158/1078-0432.CCR-10-0663. Epub 2010 Aug 24. Clin Cancer Res. 2010. PMID: 20736327 Free PMC article.
Similar articles
-
Inconsistent labeling of food effect for oral agents across therapeutic areas: differences between oncology and non-oncology products.Clin Cancer Res. 2010 Sep 1;16(17):4446-51. doi: 10.1158/1078-0432.CCR-10-0663. Epub 2010 Aug 24. Clin Cancer Res. 2010. PMID: 20736327 Free PMC article.
-
How sequential studies inform drug development: evaluating the effect of food intake on optimal bioavailability of ziprasidone.J Psychiatr Pract. 2010 Mar;16(2):103-14. doi: 10.1097/01.pra.0000369971.64908.dc. J Psychiatr Pract. 2010. PMID: 20511734
-
A new fenofibrate formulation: results of six single-dose, clinical studies of bioavailability under fed and fasting conditions.Clin Ther. 2004 Sep;26(9):1456-69. doi: 10.1016/j.clinthera.2004.09.015. Clin Ther. 2004. PMID: 15531008
-
Food Effect Studies for Oncology Drug Products.Clin Pharmacol Ther. 2017 May;101(5):606-612. doi: 10.1002/cpt.610. Epub 2017 Mar 20. Clin Pharmacol Ther. 2017. PMID: 28073144 Review.
-
Food and drug interaction: consequences for the nutrition/health status.Ann Nutr Metab. 2008;52 Suppl 1:29-32. doi: 10.1159/000115345. Epub 2008 Mar 7. Ann Nutr Metab. 2008. PMID: 18382075 Review.
Cited by
-
Phase IB Study of Selinexor, a First-in-Class Inhibitor of Nuclear Export, in Patients With Advanced Refractory Bone or Soft Tissue Sarcoma.J Clin Oncol. 2016 Sep 10;34(26):3166-74. doi: 10.1200/JCO.2016.67.6346. Epub 2016 Jul 25. J Clin Oncol. 2016. PMID: 27458288 Free PMC article. Clinical Trial.
-
Resistance to cancer chemotherapy: failure in drug response from ADME to P-gp.Cancer Cell Int. 2015 Jul 15;15:71. doi: 10.1186/s12935-015-0221-1. eCollection 2015. Cancer Cell Int. 2015. PMID: 26180516 Free PMC article.
-
Relationship between the effects of food on the pharmacokinetics of oral antineoplastic drugs and their physicochemical properties.J Pharm Health Care Sci. 2019 Dec 3;5:26. doi: 10.1186/s40780-019-0155-1. eCollection 2019. J Pharm Health Care Sci. 2019. PMID: 31827876 Free PMC article.
-
Prospective International Randomized Phase II Study of Low-Dose Abiraterone With Food Versus Standard Dose Abiraterone In Castration-Resistant Prostate Cancer.J Clin Oncol. 2018 May 10;36(14):1389-1395. doi: 10.1200/JCO.2017.76.4381. Epub 2018 Mar 28. J Clin Oncol. 2018. PMID: 29590007 Free PMC article. Clinical Trial.
-
Playing Hide-and-Seek with Tyrosine Kinase Inhibitors: Can We Overcome Administration Challenges?AAPS J. 2024 Jun 11;26(4):66. doi: 10.1208/s12248-024-00939-1. AAPS J. 2024. PMID: 38862853 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
